Showing results (241-250 of 248) with videos related to

Sort By:
Pageof 25
You have reached the last page of results.This site can display upto 248 results.
Haematologica|February 22, 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphomaAnastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, et al.
Blood|March 19, 2025
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMTNicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Blood Advances|October 13, 2021
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort studyCarlo Visco, Luigi Marcheselli, Roberto Mina, et al.
Haematologica|June 26, 2025
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practiceAnna Maria Frustaci, Andrea Galitzia, Mariano Lucignano, et al.
The Lancet. Haematology|August 18, 2020
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyFrancesco Passamonti, Chiara Cattaneo, Luca Arcaini, et al.
Hematological Oncology|December 29, 2025
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World StudyErnesto Vigna, Enrica Antonia Martino, Annalisa Pitino, et al.
Blood Advances|January 7, 2026
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian CohortEnrica Antonia Martino, Annalisa Pitino, Ernesto Vigna, et al.
Pageof 25